Introduction
Recent decisions by the U.S. Food and Drug Administration (FDA) are reshaping the landscape for compounded versions of blockbuster weight-loss and diabetes medications. The agency has proposed removing the active ingredients semaglutide (used in Wegovy and Ozempic from Novo Nordisk) and tirzepatide (used in Mounjaro and Zepbound from Eli Lilly) from a list of substances that can be used by large-scale compounding facilities. This move, if finalized, will end a controversial period where compounded versions offered cheaper access amid shortages. Additionally, a leadership change at the FDA’s Center for Biologics Evaluation and Research (CBER) adds another layer of regulatory evolution. This guide helps you understand the steps to take as a patient, prescriber, or compounder to adapt to these developments.
What You Need
- Basic understanding of drug compounding (custom-made medications) and the difference between traditional pharmacy compounding (503A) and large-scale outsourcing facilities (503B).
- Knowledge of the specific drugs affected: semaglutide (for diabetes and weight loss) and tirzepatide (for diabetes and weight loss).
- A list of your current medications or those you are considering.
- Contact information for your healthcare provider and/or a pharmacist familiar with compounding regulations.
- Access to FDA announcements and trusted news sources (e.g., STAT News) for updates.
Step-by-Step Guide
Step 1: Understand the FDA’s Proposed Decision and Its Rationale
The FDA determined that there is "no clinical need" to allow large compounding facilities (503B) to produce bulk supplies of semaglutide or tirzepatide. Why does this matter? Compounded versions of these drugs have surged in popularity because they offer lower-cost alternatives when brand-name drugs are in shortage. The agency’s proposal is a victory for Novo Nordisk and Eli Lilly, who argue that compounding undermines their patents and safety oversight. Key takeaway: Once finalized, large-scale compounders must stop making these copies, affecting patient access unless brand-name supply stabilizes.
Step 2: Identify the Drugs and Facilities Impacted
The proposal targets only semaglutide and tirzepatide—the active ingredients—not all GLP-1 drugs. It applies specifically to outsourcing facilities (503B) that produce large quantities without patient-specific prescriptions. Traditional pharmacies (503A) that compound for individual patients are less affected, but state boards may follow suit. Check your medication: If you are using a compounded version from a bulk supplier, it likely contains one of these two ingredients. Verify with your pharmacy.
Step 3: Assess Your Current Treatment Situation
If you are currently taking a compounded form of semaglutide or tirzepatide, do not panic. The FDA’s proposal is not yet final—there will be a comment period and possible phased implementation. However, start evaluating your options:
- If you have insurance, check coverage for brand-name Wegovy, Ozempic, Mounjaro, or Zepbound.
- If shortages exist (still possible as of mid-2025), discuss alternative treatments like liraglutide or other GLP-1 agonists.
- Assess the cost difference and any financial assistance programs from manufacturers.
Step 4: Consult with Your Healthcare Provider
Schedule an appointment—telehealth or in-person—to discuss the regulatory changes. Key questions to ask:
- “Should I switch to a brand-name version now, or wait?”
- “What are the risks of continuing a compounded version that may become illegal?”
- “Are there other medications that can achieve similar outcomes?”
- “Can I get a prescription written specifically for a 503A pharmacy that compounds for my needs?”
Your provider can also monitor for safety issues, as compounded products lack the same quality controls as FDA-approved drugs.
Step 5: Consider the Implications of the CBER Leadership Change
The FDA named Katherine Szarama as acting director of CBER, replacing Vinay Prasad, who left after a controversial tenure involving rare disease drugs and vaccines. Why this matters for you: CBER regulates vaccines and gene therapies, but also plays a role in biologic drugs and supply chain decisions. A new director may influence future compounding policies, especially for biologic-based weight loss drugs. Stay informed about Szarama’s priorities—whether she will be a career insider or a reformer—and watch for any shifts in enforcement. Originally, Houman Hemmati, a physician and biotech executive with media presence, was rumored as a candidate; his non-appointment may signal a preference for internal candidates.
Step 6: Stay Informed and Plan Ahead
Follow these actions to remain proactive:
- Subscribe to FDA alerts or reputable news sources like STAT News for updates on the final rule.
- Monitor the comment period deadlines; if you are a patient advocate or provider, consider submitting a public comment.
- If you are a compounder, prepare for compliance by diversifying product lines or shifting to 503A patient-specific compounding.
- Keep records of your current prescriptions and compounding invoices in case grandfathered use is allowed during transition.
Tips for Success
- Don’t abruptly stop your medication. Abrupt discontinuation can lead to side effects. Work with your doctor on a plan.
- Verify the source. Ensure any compounded product comes from a state-licensed pharmacy that follows USP standards.
- Explore patient assistance programs. Both Novo Nordisk and Eli Lilly offer savings cards and financial aid for eligible patients.
- Document everything. Keep a log of your treatment history, costs, and any correspondence with your pharmacy.
- Watch for shortages. Drug shortages may reappear as the compounding supply disappears; have a backup plan.
- Engage with advocacy groups. Organizations like the Obesity Action Coalition can provide updates and support.
- Be wary of illegal copies. Avoid online pharmacies that sell unapproved GLP-1 drugs; they may contain unsafe ingredients.
By following these steps, you can navigate the changing regulatory environment with confidence. Remember, the FDA’s goal is safety, but your health journey requires personalized advice. Stay informed, ask questions, and prioritize evidence-based treatments.